Copyright
©2013 Baishideng Publishing Group Co.
World J Gastroenterol. Oct 7, 2013; 19(37): 6199-6206
Published online Oct 7, 2013. doi: 10.3748/wjg.v19.i37.6199
Published online Oct 7, 2013. doi: 10.3748/wjg.v19.i37.6199
Characteristics | SEMS | cSEMS |
Stents | 16 (50) | 16 (50) |
Male gender | 7 (44) | 10 (63) |
Age (yr), mean ± SD (range) | 70 ± 11 (50-85) | 71 ± 11 (50-84) |
Localization | ||
Jejunum, n | 3 | 0 |
Duodenum, n | 13 | 16 |
Disease | ||
Pancreatic carcinoma, n | 6 | 7 |
Cholangiocellular carcinoma, n | 3 | 2 |
Gallbladder carcinoma, n | 1 | 2 |
Gastric cancer, n | 3 | 2 |
Colorectal cancer, n | 2 | 0 |
Breast cancer metastasis, n | 1 | 0 |
Stenosis due to duodenal ulcer perforation, n | 0 | 3 |
Balloon dilatation of the stent | 3 (19) | 2 (13) |
Concomitant biliary drainage | 9 (56) | 8 (50) |
Complications | SEMS | cSEMS | P value |
Duration of procedure (min), median (range) | 60 (40-121) | 60 (31-160) | 0.867 |
Migration | 0 (0) | 9 (56) | 0.002 |
Time until migration (d), mean ± SD (range) | - | 30 ± 52 (1-161) | NA |
Tumor overgrowth | 3 (19) | 2 (13) | 0.725 |
Tumor ingrowth, n | 0 | 0 | NA |
Time until tumor overgrowth (d), mean ± SD (range) | 143 ± 95 (39-224) | 96 ± 105 (22-170) | 0.572 |
Overall survival (d), median, range | 40 (3-275) | 75 (11-426) | 0.431 |
Study | Patients, stents | Site of tumor obstruction | Tumor overgrowth | Migration | Bleeding | Perforation |
Costamagna et al[1] | 202, 212 | Endoscopic duodenal stenting | 12.4% | 1.5% | 3.0% | 0.5% |
van Hooft et al[2] | 50, 57 | Endoscopic stenting for gastric outlet obstruction | 21.0% | 4.0% | 0.0% | 0.0% |
Jeong et al[4] | 25, 28 | Gastrojejunostomy, esophagojejunostomy, cSEMS | 17.0% | 4.0% | 0.0% | 1.0% |
Chandrasegaram et al[7] | 26, 31 | Endoscopic stenting vs operative gastrojejunostomy | 12.0% | 0.0% | 0.0% | 0.0% |
Jang et al[17] | 583, 603 | Peripyloric region, nonperipyloric region, duodenum alone anastomosis (Billroth I, Billroth II), jejunum | 3.8% | NM | NM | < 1.0% |
Kim et al[25] | 50, 50 | Endoscopic stenting for malignant gastroduodenal obstructions | 18.0% | 10.0% | 0.0% | 0.0% |
Wong et al[26] | 6, 6 | Surgical vs endoscopic palliation | NM | NM | NM | NM |
Mosler et al[27] | 36, 52 | Endoscopic stenting of nonesophageal upper gastrointestinal stenosis | 11.0% | 14.0% | 0.0% | 6.0% |
Kim et al[28] | 213, 236 | Malignant gastroduodenal obstruction | 7.0% | 4.0% | 1.0% | 0.0% |
Bang et al[29] | 134, 132 | Endoscopic treatment for malignant antropyloric and duodenal | cSEMS 5.7%SEMS 19.0% | cSEMS 26.4% SEMS 6.3% | 2.2% | < 1.0% |
Keränen et al[30] | 104, 130 | Endoscopic treatment for malignant gastric outlet obstruction | 18.0% | 0.0% | 0.0% | 1.9% |
Ahn et al[31] | 47, 52 | Malignant gastroduodenal obstruction, uncovered SEMS | 11.0% | 2.0% | 0.0% | 4.0% |
Canena et al[32] | 74, 80 | Endoscopic stenting for gastric outlet obstruction | 9.5% | 0.0% | 1.4% | 0.0% |
Cha et al[33] | 85, 85 | Endoscopic stenting for gastroduodenal obstruction | 29.0% | 4.0% | 4.0% | 4.0% |
Own data | 20, 32 | Small bowel/duodenum | cSEMS 13.0%SEMS 19.0% | cSEMS 56.0%SEMS 0.0% | 0.0% | 0.0% |
-
Citation: Waidmann O, Trojan J, Friedrich-Rust M, Sarrazin C, Bechstein WO, Ulrich F, Zeuzem S, Albert JG. SEMS
vs cSEMS in duodenal and small bowel obstruction: High risk of migration in the covered stent group. World J Gastroenterol 2013; 19(37): 6199-6206 - URL: https://www.wjgnet.com/1007-9327/full/v19/i37/6199.htm
- DOI: https://dx.doi.org/10.3748/wjg.v19.i37.6199